American College of Cardiology 71st Scientific Sessions: Science Preview, April 4, 2022

News
Slideshow

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

On the final day of ACC 2022, check out late-breaking clinical trials during 3 different sessions.

A few higlights: Edoxaban vs DAPT post-TAVR, finerenone and cardiorenal outcomes in special CVD populations, canakinumab and residual inflammatory risk, and a report on an international ACC program to improve treatment for STEMI.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Sunday, April 3, 2022 Late Breaking Clincial Trials

More News from ACC on Patient Care

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Sydney Jennings
July 14th 2025
Article

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
July 8th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Grace Halsey
July 8th 2025
Article

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes / image credit ADA Julio Rosenstock, MD

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults With Type 2 Diabetes

Grace Halsey
June 23rd 2025
Article

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Healthy Low-Carb or Low-Fat Diets Linked to Lower CVD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

Healthy Low-Carb or Low-Fat Diets Linked to Lower CVD Risk: Daily Dose

Sydney Jennings
June 19th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.